You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兩連板千金藥業(600479.SH):利巴韋林顆粒對業績無重大影響
格隆匯 02-06 18:16

格隆匯2月6日丨千金藥業(600479.SH)公佈,公司股票交易於2020年2月4日、2月5日和2月6日連續三個交易日收盤價格漲幅偏離值超過20%,根據《上海證券交易所交易規則》的有關規定,屬於股票交易異常波動。

公司近期經營情況正常,內外部經營環境未發生重大變化。公司佔有控股子公司湖南千金湘江藥業股份有限公司(以下簡稱“千金湘江藥業”)51%的股權。千金湘江藥業於2015年10月獲得鹽酸阿比朵爾片的臨牀批件,但至今未獲得生產批件。目前公司沒有該產品的生產及銷售,對公司業績沒有影響。千金湘江藥業的產品利巴韋林顆粒2018年度營業收入4564萬元,佔公司營業收入的比例為1.37%;2019年1-3季度營業收入2307萬元,佔公司營業收入的比例為0.88%。當前該產品的銷售對公司業績未產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account